Patents by Inventor Michael R. Hayden

Michael R. Hayden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10731160
    Abstract: The present invention relates to compositions and methods of use thereof for inhibiting mutant HTT mRNA transcription or CAG-expanded HTT protein expression in a cell, comprising contacting the cell with an effective amount of an oligomer targeting a differentiating polymorphism, wherein the differentiating polymorphism is selected from rs72239206, rs363107, rs362313, rs2530595, rs113407847. Specific oligomer sequences are also provided.
    Type: Grant
    Filed: January 7, 2020
    Date of Patent: August 4, 2020
    Assignee: The University of British Columbia
    Inventors: Amber L. Southwell, Christopher Kay, Michael R. Hayden, Nicholas S. Caron
  • Publication number: 20200199595
    Abstract: The present invention relates to compositions and methods of use thereof for inhibiting mutant HTT mRNA transcription or CAG-expanded HTT protein expression in a cell, comprising contacting the cell with an effective amount of an oligomer targeting a differentiating polymorphism, wherein the differentiating polymorphism is selected from rs72239206, rs363107, rs362313, rs2530595, rs113407847. Specific oligomer sequences are also provided.
    Type: Application
    Filed: January 7, 2020
    Publication date: June 25, 2020
    Applicant: The University of British Columbia
    Inventors: Amber L. Southwell, Christopher Kay, Michael R. Hayden, Nicholas S. Caron
  • Patent number: 10533172
    Abstract: The present invention relates to compositions and methods of use thereof for inhibiting mutant HTT mRNA transcription or CAG-expanded HTT protein expression in a cell, comprising contacting the cell with an effective amount of an oligomer targeting a differentiating polymorphism, wherein the differentiating polymorphism is selected from rs72239206, rs363107, rs362313, rs2530595, rs113407847. Specific oligomer sequences are also provided.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: January 14, 2020
    Assignee: The University of British Columbia
    Inventors: Amber L. Southwell, Christopher Kay, Michael R. Hayden, Nicholas S. Caron
  • Publication number: 20170253877
    Abstract: The present invention relates to compositions and methods of use thereof for inhibiting mutant HTT mRNA transcription or CAG-expanded HTT protein expression in a cell, comprising contacting the cell with an effective amount of an oligomer targeting a differentiating polymorphism, wherein the differentiating polymorphism is selected from rs72239206, rs363107, rs362313, rs2530595, rs113407847. Specific oligomer sequences are also provided.
    Type: Application
    Filed: September 18, 2015
    Publication date: September 7, 2017
    Applicant: The University of British Columbia
    Inventors: Amber L. Southwell, Christopher Kay, Michael R. Hayden, Nicholas S. Caron
  • Patent number: 9290751
    Abstract: The invention provides for the use of a therapeutic derived from a truncated lipoprotein lipase protein (LPL S447X), including nucleic acids encoding such proteins, for the treatment of conditions including LPL responsive conditions, such as cardiovascular disease, hypertension, LPL deficiency, high triglyceride levels, low HDL-cholesterol levels or atherosclerosis.
    Type: Grant
    Filed: July 4, 2014
    Date of Patent: March 22, 2016
    Inventors: Michael R. Hayden, John P. Kastelein
  • Patent number: 8957071
    Abstract: The disclosure provides methods and compositions for treating a vascular, autoimmune, and/or inflammatory disease, or a condition associated therewith, with a dose of an inosine monophosphate dehydrogenase (IMPDH) inhibitor effective to treat the vascular, autoimmune and/or inflammatory disease, or associated condition but that does not produce immunosuppression sufficient to reduce the risk of allograft rejection. These lower doses of the immunosuppressant avoid the adverse consequences of severe immunosuppression while providing effective treatment of the vascular, autoimmune and/or inflammatory disease.
    Type: Grant
    Filed: May 5, 2008
    Date of Patent: February 17, 2015
    Assignees: Aspreva Pharmaceuticals S.A., Aspreva Pharmaceuticals Corp.
    Inventors: Richard Glickman, Michael R. Hayden, Noel Hall
  • Publication number: 20150030581
    Abstract: The invention provides for the use of a therapeutic derived from a truncated lipoprotein lipase protein (LPL S447X), including nucleic acids encoding such proteins, for the treatment of conditions including LPL responsive conditions, such as cardiovascular disease, hypertension, LPL deficiency, high triglyceride levels, low HDL-cholesterol levels or atherosclerosis.
    Type: Application
    Filed: July 4, 2014
    Publication date: January 29, 2015
    Inventors: Michael R. HAYDEN, John P. Kastelein
  • Publication number: 20140147516
    Abstract: Methods of determining a subject's ototoxicity risk from administration of a pharmacotherapeutic compound having an ototoxicity risk, methods of administering a pharmacotherapeutic compound having an ototoxicity risk and oligonucleotides, peptide nucleic acids, arrays, and addressable collections for performing embodiments of the methods are provided herein.
    Type: Application
    Filed: December 3, 2013
    Publication date: May 29, 2014
    Applicant: The University of British Columbia
    Inventors: Michael R. Hayden, Bruce Carleton, Colin Ross
  • Patent number: 8715968
    Abstract: The invention features ABC1 nucleic acids and polypeptides for the diagnosis and treatment of abnormal cholesterol regulation. The invention also features methods for identifying compounds for modulating cholesterol levels in an animal (e.g., a human).
    Type: Grant
    Filed: December 23, 2003
    Date of Patent: May 6, 2014
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Michael R. Hayden, Angela R. Brooks-Wiison, Simon N. Pimstone
  • Publication number: 20130164262
    Abstract: Recombinant viruses comprising a heterologous DNA sequence coding for a lipase involved in lipoprotein metabolism. The invention also concerns the preparation and use in therapy of said recombinant viruses, especially for the treatment or prevention of dyslipoproteinemia-related pathologies.
    Type: Application
    Filed: August 13, 2012
    Publication date: June 27, 2013
    Inventors: Patrick Benoit, Patrice Denefle, Michel Perricaudet, M.E. Suzanne Lewis, Michael R. Hayden
  • Publication number: 20110306608
    Abstract: The disclosure provides methods and compositions for the treatment of vascular, autoimmune and inflammatory diseases using a combination of an inosine monophosphate dehydrogenase (IMPDH) inhibitor and a HMG CoA reductase inhibitor.
    Type: Application
    Filed: April 5, 2011
    Publication date: December 15, 2011
    Inventors: Michael R. Hayden, Noel Hall
  • Patent number: 8067219
    Abstract: The invention features ABC1 nucleic acids and polypeptides for the diagnosis and treatment of abnormal cholesterol regulation. The invention also features methods for identifying compounds for modulating cholesterol levels in an animal (e.g., a human).
    Type: Grant
    Filed: September 14, 2010
    Date of Patent: November 29, 2011
    Assignees: Xenon Pharmaceuticals Inc., University of British Columbia
    Inventors: Michael R. Hayden, Angela R. Brooks-Wilson, Simon N. Pimstone
  • Publication number: 20110201673
    Abstract: The invention provides for the use of a therapeutic derived from a truncated lipoprotein lipase protein (LPL S447X), including nucleic acids encoding such proteins, for the treatment of conditions including LPL responsive conditions, such as cardiovascular disease, hypertension, LPL deficiency, high triglyceride levels, low HDL-cholesterol levels or atherosclerosis.
    Type: Application
    Filed: October 5, 2010
    Publication date: August 18, 2011
    Inventors: Michael R. Hayden, John J.P. Kastelein
  • Patent number: 7971395
    Abstract: A multipurpose adjustable panel system having support beams continuously adjustable between zero pitch and a pitch exceeding zero, wherein support beam pitch is influenced by vertical adjustment of support post assemblies and by horizontal spacing of support post assemblies. Multiple mounting fixtures are incorporated to accommodate beam pitch adjustment including pivotable beam support fixtures adjustably and positionably secured along the bottoms of the beams and pivotable panel support node fixtures adjustably and positionably secured along the tops of the beams, the pivotable beam support fixtures and the pivotable panel support node fixtures enabling ready adjustment of the pitch of the beams.
    Type: Grant
    Filed: January 12, 2006
    Date of Patent: July 5, 2011
    Assignee: Staging Concepts, Inc.
    Inventors: Todd S Vigil, Steven J. Zechmeister, Michael R. Hayden
  • Publication number: 20110104257
    Abstract: Methods of determining a subjects ototoxicity risk from administration of platinum-coordinating compounds having an ototoxicity risk, methods of administering a platinum-coordinating compound having an ototoxicity risk and oligonucleotides, peptide nucleic acids, arrays and addressable collections for performing embodiments of the methods are provided herein.
    Type: Application
    Filed: April 14, 2009
    Publication date: May 5, 2011
    Inventors: Michael R. Hayden, Bruce Carleton, Colin Ross
  • Publication number: 20110065147
    Abstract: The invention features ABC1 nucleic acids and polypeptides for the diagnosis and treatment of abnormal cholesterol regulation. The invention also features methods for identifying compounds for modulating cholesterol levels in an animal (e.g., a human).
    Type: Application
    Filed: September 14, 2010
    Publication date: March 17, 2011
    Inventors: Michael R. Hayden, Angela R. Brooks-Wilson, Simon N. Pimstone
  • Publication number: 20110060014
    Abstract: The use of screening assays based on the role of human stearoyl-CoA desaturase-1 (“hSCD1”) in human diseases, disorders or conditions relating to serum levels of triglyceride, VLDL, HDL, LDL, total cholesterol, or production of secretions from mucous membranes, monounsaturated fatty acids, wax esters, and the like, is disclosed. Also disclosed are conventions useful in the prevention and/or treatment of such diseases.
    Type: Application
    Filed: September 9, 2010
    Publication date: March 10, 2011
    Inventors: Michael R. Hayden, Alison J. Brownlie, James M. Ntambi, Makoto Miyazaki, Mark P. Gray-Keller, Alan D. Attie
  • Patent number: 7895792
    Abstract: A portable platform-support system provides an external platform comer for supporting a platform surface structure; the system having a rigid comer-support apparatus having a non-integrating outer-facing portion with opposing outer edges, an inner portion, and a recessed pocket; a channel member having an elongated shape, a slot aligning with the recessed pocket, and an upper surface to provide support to the platform surface structure; and a reinforcement member securely coupled to and extending from the inner portion with the reinforcement member to securely support the channel member.
    Type: Grant
    Filed: July 29, 2009
    Date of Patent: March 1, 2011
    Assignee: Staging Concepts, Inc.
    Inventors: Michael R. Hayden, Danny D. Scott
  • Patent number: D863519
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: October 15, 2019
    Assignee: Rheem Manufacturing Company
    Inventors: Christopher M. Hayden, Sergiu G. Mihu, Eric R. Jurczyszak, Curtis J. Keohane, Michael J. Medica
  • Patent number: D870868
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: December 24, 2019
    Assignee: Rheem Manufacturing Company
    Inventors: Christopher M. Hayden, Sergiu G. Mihu, Eric R. Jurczyszak, Curtis J. Keohane, Michael J. Medica